DEF 14A: RFAC Seeks SPAC Extension for Nanyang Biologics Deal

RF Acquisition Corp II is holding an Extraordinary General Meeting to vote on extending its business combination deadline to August 15, 2026, to complete its merger with Nanyang Biologics.

Summary

• RF Acquisition Corp II (RFAC), a Special Purpose Acquisition Company (SPAC), is seeking to extend its deadline to complete an initial business combination.
• The current deadline for RFAC to consummate a business combination is November 15, 2025.
• RFAC proposes to amend its charter and trust agreement to allow for up to nine additional one-month extensions, pushing the final deadline to August 15, 2026.
• On October 2, 2025, RFAC entered into a Business Combination Agreement with NYB Holdings Limited, Amalgamation Sub, and Nanyang Biologics Pte. Ltd., but there is no guarantee the combination will be consummated.
• Each one-month extension requires the Sponsor or its affiliates to deposit $0.03 for each Public Share not redeemed, up to a maximum of $60,000 per extension, in exchange for a non-interest bearing, unsecured promissory note.
• Public shareholders have the right to redeem their shares for cash at approximately $10.68 per share, based on the Trust Account balance of $122,859,040.74 as of the September 30, 2025 Record Date.
• The Board of Directors unanimously recommends that shareholders vote FOR the Extension Amendment Proposal, the Trust Agreement Amendment Proposal, and the Adjournment Proposal (if necessary).

Sentiment

Score: 4

Explanation: While a target (Nanyang Biologics) has been identified, the need for an extension indicates challenges in closing the deal within the original timeframe. The extension payments by the sponsor are positive, but the lack of obligation and the potential for redemptions reducing the trust account balance introduce uncertainty. The risks associated with SPAC rules and potential delisting are also concerning.

Positives

• RFAC has identified a target, Nanyang Biologics, and entered into a Business Combination Agreement, indicating progress towards a merger.
• The proposed extension provides RFAC with up to an additional nine months (until August 15, 2026) to complete the business combination, which the Board believes is necessary given the complexities involved.
• Public shareholders are provided with redemption rights at approximately $10.68 per share, offering an exit option if they do not wish to remain invested for the extended period.
• RFAC has agreed to waive its right to withdraw up to $100,000 of interest accrued on the Trust Account for dissolution expenses, which would increase the amount available to public shareholders upon liquidation if a business combination is not completed.

Negatives

• The company explicitly states that the current termination date of November 15, 2025, will not provide sufficient time to complete the Business Combination, indicating a delay in the merger process.
• There is no guarantee that the Business Combination with Nanyang Biologics will be consummated, even if the extension proposals are approved.
• The Sponsor and its affiliates are not obligated to fund the extension payments, introducing uncertainty regarding the availability of funds for extensions.
• If RFAC liquidates, public shareholders' rights will expire worthless, and claims of creditors may take priority over public shareholders.
• The redemption price of approximately $10.68 per Public Share is slightly lower than the Nasdaq closing price of $10.74 on the Record Date, resulting in a small loss for redeeming shareholders compared to selling in the open market.
• Public shareholders are restricted from redeeming more than an aggregate of 15% of the Public Shares without the company's prior consent, limiting large redemptions.
• The Sponsor, directors, and officers have financial interests that may differ from public shareholders, as their Founder Shares (acquired for ~$0.008 per share) and Private Placement Units would become worthless if a business combination is not completed.

Risks

• There is no assurance that the Extension Amendment, Trust Agreement Amendment, and Extensions will enable RFAC to complete an initial Business Combination by the last Extended Date, August 15, 2026.
• Shareholder redemptions in connection with the Extension Amendment Proposal could leave RFAC with insufficient cash to consummate an initial Business Combination on commercially acceptable terms or at all.
• The market price and liquidity of RFAC's Public Shares and other securities may be volatile, and shareholders may be unable to dispose of their shares at favorable prices.
• New SEC rules (SPAC Rules) may increase costs and the time needed to complete a Business Combination, potentially forcing RFAC to liquidate earlier.
• RFAC could be deemed an investment company under the Investment Company Act of 1940, which would impose burdensome compliance requirements, severely restrict its activities, and potentially lead to liquidation.
• The proposed Business Combination with a foreign target (Nanyang Biologics) may be subject to review or approval by U.S. or foreign regulatory authorities, which could delay or prevent the transaction.
• Nasdaq may delist RFAC's securities if redemptions reduce the number of public shares, leading to limited market quotations, reduced liquidity, and additional trading restrictions.
• State securities regulators might use their powers to hinder the sale of securities of blank check companies, especially if RFAC's securities are delisted from Nasdaq.

Future Outlook

The Board believes the current termination date of November 15, 2025, will not provide sufficient time to complete the Business Combination with Nanyang Biologics. If the extension proposals are approved, RFAC will continue its efforts to consummate the Business Combination by the new extended deadline of August 15, 2026. However, there is no assurance that the Business Combination will be completed even with the extension.

Management Comments

• "The Board has determined that it is in the best interests of RFAC to seek an extension of the Termination Date and have RFAC shareholders approve the Extension Amendment Proposal and the Trust Agreement Amendment Proposal to allow for additional time to consummate a Business Combination."
• "The Board believes that the current Termination Date will not provide sufficient time to complete a Business Combination."
• "Given RFACs commitment of time, effort and financial resources to date with respect to identifying a Business Combination target, circumstances warrant providing shareholders with additional time and opportunity to consider a prospective Business Combination."
• "Even if the Extension Amendment Proposal and Trust Agreement Amendment Proposal are approved and the Extension Amendment, Trust Agreement Amendment and Extension are implemented, there is no assurance that RFAC will be able to consummate a Business Combination within the Combination Period, as extended, given the actions that must occur prior to closing of a Business Combination."

Industry Context

This filing reflects a common challenge faced by Special Purpose Acquisition Companies (SPACs) in the current market environment, where identifying and consummating suitable business combinations within initial deadlines can be difficult. The need for an extension, despite having a target identified (Nanyang Biologics), suggests complexities in deal execution, regulatory approvals, or financing conditions. The mention of new SEC rules (SPAC Rules) highlights increased regulatory scrutiny and potential compliance burdens impacting the SPAC industry as a whole, which can further complicate and extend the de-SPAC process.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The Sponsor and its affiliates or designees will fund the extension payments ($0.03 per public share, up to $60,000 per month) into the Trust Account in exchange for a non-interest bearing, unsecured promissory note.
• The Sponsor, directors, and officers hold 3,075,000 Founder Shares (acquired for $25,000) and Private Placement Units, which would become worthless if a business combination is not completed, creating a strong incentive for them to approve the extension.
• The Existing Charter contains a waiver of the corporate opportunity doctrine, which could allow RFAC directors to pursue business opportunities for other entities, potentially creating conflicts of interest.

Stakeholder Impact

• Shareholders (Public): Have the option to redeem shares at approximately $10.68 per share if they do not wish to extend, or remain invested for the potential business combination with Nanyang Biologics. They face the risk of losing their investment if liquidation occurs and creditors' claims take priority, and potential for reduced liquidity if RFAC's securities are delisted.
• Shareholders (Sponsor/Initial): Their Founder Shares and Private Placement Units, with a market value of over $30 million, are at risk of becoming worthless if the extension is not approved and a business combination is not completed. They have a strong financial incentive to approve the extension and complete a deal.
• Nanyang Biologics: The proposed target company, whose business combination with RFAC is contingent on the extension being approved. A failure to extend could jeopardize the merger.
• Creditors: In the event of liquidation, claims of creditors may take priority over public shareholders, potentially reducing the amounts distributed to shareholders.

Next Steps

• Hold an Extraordinary General Meeting on November 10, 2025, to vote on the Extension Amendment Proposal, Trust Agreement Amendment Proposal, and Adjournment Proposal.
• If approved, amend the Existing Charter and Trust Agreement to extend the business combination deadline to August 15, 2026.
• Continue efforts to consummate the Business Combination with Nanyang Biologics.
• If a Business Combination is approved, a separate shareholder meeting will be held to vote on it, with associated redemption rights.
• If the extension proposals are not approved and a Business Combination is not consummated by November 15, 2025 (or the last extended date), RFAC will liquidate and redeem public shares.

Key Dates

Recommendation

The filing presents a critical juncture for RFAC. For shareholders who are optimistic about the proposed business combination with Nanyang Biologics and are willing to tolerate the extended timeline and associated risks, holding shares to participate in the potential merger is a viable strategy. The redemption option provides a floor for those who prefer to exit now, albeit at a slight discount to the current market price. Given the uncertainty surrounding the completion of the business combination and the inherent risks of SPACs, a 'hold' recommendation acknowledges both the potential upside of a successful merger and the downside protection offered by redemption, allowing investors to make an informed decision based on their risk appetite and conviction in the Nanyang Biologics deal.

Keywords

SPAC, Business Combination, Extension, Nanyang Biologics, RF Acquisition Corp II, Proxy Statement, Redemption Rights, Trust Account, SEC Filing, Corporate Governance, Shareholder Vote, Merger, De-SPAC